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1. INTRODUCTION {#cam43180-sec-0005}
===============

Solid pseudopapillary neoplasms (SPNs) of the pancreas are uncommon, borderline tumors, accounting for approximately 1%‐2.7% of all pancreatic tumors.[^1^](#cam43180-bib-0001){ref-type="ref"}, [^2^](#cam43180-bib-0002){ref-type="ref"} Recently, the incidence of SPN has been steadily growing,[^3^](#cam43180-bib-0003){ref-type="ref"}, [^4^](#cam43180-bib-0004){ref-type="ref"} and with the development and extensive use of imaging, the number of asymptomatic patients with SPN will increase.[^5^](#cam43180-bib-0005){ref-type="ref"} It has already attracted increasing attention from clinicians and researchers.

To date, surgical resection remains the optimal treatment for resectable SPN.[^6^](#cam43180-bib-0006){ref-type="ref"} Nevertheless, it has been reported that up to 19% of patients with SPN suffer from distant metastasis or localized invasion.[^7^](#cam43180-bib-0007){ref-type="ref"} Moreover, recurrence after radical resection can occur in up to 9% of cases,[^1^](#cam43180-bib-0001){ref-type="ref"}, [^7^](#cam43180-bib-0007){ref-type="ref"} and even after re‐resections, recurrence can still occur.[^6^](#cam43180-bib-0006){ref-type="ref"} There is no consensus on treatment for unresectable SPNs, and postoperative recurrence and metastasis, which indicates that other adjuvant treatments should be taken into consideration.

In addition, it has been established that SPN predominantly occurs in women with a women‐to‐men ratio of 10 to 1[^7^](#cam43180-bib-0007){ref-type="ref"} and usually affects women of reproductive age.[^8^](#cam43180-bib-0008){ref-type="ref"}, [^9^](#cam43180-bib-0009){ref-type="ref"} This discrepancy suggests that sex could be a possible epidemiologic risk factor.[^10^](#cam43180-bib-0010){ref-type="ref"} Several studies reported that progesterone receptors were present in 79%‐100% of patients with SPN.[^11^](#cam43180-bib-0011){ref-type="ref"}, [^12^](#cam43180-bib-0012){ref-type="ref"} All of the abovementioned facts suggest that sex hormones may play a role in the pathogenesis of SPN. We hypothesized that there was likely a difference between male and female patients with SPN. However, to our knowledge, a limited number of small case studies comparing men and women with SPN are available, and some controversies remain. Therefore, this study not only aimed to examine the clinicopathological features and the value of surgical treatments for SPN but also to compare the clinical behavior and prognosis between men and women with SPN based on a relatively large cohort study. It may provide inspiration for different management strategies for male and female patients and imply the possibility of hormone therapy for SPN.

2. METHODS {#cam43180-sec-0006}
==========

2.1. Data collection and study cohort {#cam43180-sec-0007}
-------------------------------------

Data from this study were collected from the the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute using SEER\*Stat 8.3.6 software. We restricted our study to the SEER database (2004‐2017) because detailed Collaborative Stage (CS) data of SPN were not available before 2004. Patients were enrolled in this study if[^1^](#cam43180-bib-0001){ref-type="ref"} the ICD Histologic Type ICD‐O‐3 code was 8452 or 8453[^2^](#cam43180-bib-0002){ref-type="ref"}; SPN was the only primary malignant tumor[^3^](#cam43180-bib-0003){ref-type="ref"}; patients were diagnosed with positive histology and/or cytology[^4^](#cam43180-bib-0004){ref-type="ref"}; clinicopathological information for sex, age at diagnosis, year of diagnosis, race, marital status, tumor location, tumor size, T‐classification, number of positive regional nodes, number of examined regional nodes, N‐classification, distant metastasis status, summary stage, surgery types, and radiotherapy or chemotherapy experience was included; and[^5^](#cam43180-bib-0005){ref-type="ref"} the vital status and cause of death were known, and patients were diagnosed more than 1 month prior to death. The detailed process of selecting patients is shown in Figure [1](#cam43180-fig-0001){ref-type="fig"}.

![Flow diagram of patients selection in our study from the SEER database 2004‐2017](CAM4-9-6030-g001){#cam43180-fig-0001}

2.2. Study variables {#cam43180-sec-0008}
--------------------

The following variables were obtained from the selected data: sex, age at diagnosis, year of diagnosis, race, marital status, tumor location, tumor size, T‐classification, number of positive regional nodes, number of examined regional nodes, N‐classification, distant metastases status, summary stage, surgery types, radiotherapy or chemotherapy experience, vital status, cause of death, and survival months. According to seer coding manuals (<https://seer.cancer.gov/tools/codingmanuals/>), all data were precisely decoded. In this study, operation methods are divided into operative treatment (included local excision of tumor, partial pancreatectomy, partial or local pancreatectomy and duodenectomy without distal/partial gastrectomy, Whipple\'s procedure, extended pancreatoduodenectomy, total pancreatectomy with subtotal gastrectomy or duodenectomy, NanoKnife, and irreversible electroporation) and nonoperative treatment.

2.3. Statistical analysis {#cam43180-sec-0009}
-------------------------

The patients' demographic and clinicopathological parameters were summarized by descriptive statistics. Reverse Kaplan‐Meier methods were performed to estimate the median follow‐up time. The chi‐square test or Fisher\'s exact test was used to compare patient characteristics between the male and female groups. We used Kaplan‐Meier methods to analyze overall survival (OS) and disease‐specific survival (DSS) and log‐rank tests to evaluate the differences between subgroups. Univariate and multivariate Cox regression analyses were used to assess independent prognostic risk factors associated with the OS and DSS of patients with SPN. We presented the results as hazard ratios (HRs) and 95% confidence intervals (CIs). All of the statistical analyses were performed using GraphPad Prism 8 (GraphPad Software) and SPSS Statistics 22.0 (IBM). Differences were considered to be statistically significant when *P* values were less than .05.

3. RESULTS {#cam43180-sec-0010}
==========

3.1. Patient demographic and clinicopathological parameters {#cam43180-sec-0011}
-----------------------------------------------------------

In total, 378 patients were identified in this study, and their characteristics in the entire cohort are listed in Table [1](#cam43180-tbl-0001){ref-type="table"}. The age of the patients ranged from 8 to 91 years (mean, 50.8 years). There were 277 (73.3%) patients who were white. Fewer than half of the patients were male (34.9%) and unmarried (32.8%). Regarding treatment, most patients never received radiotherapy (90.7%) or chemotherapy (78.8%) treatment. Overall, 330 (87.3%) patients had surgery experience, whereas 48 (12.7%) patients did not undergo surgery. Over half of the SPNs occurred in the head of the pancreas (53.4%), followed by the tail (30.4%) and body of the pancreas (14.3%). The tumor size was more than 40 mm in 191 patients, who accounted for 50.5% of 378 cases. More than half of patients with SPN were diagnosed at the localized stage (57.9%) without positive lymph nodes (84.7%) or distant metastasis (92.3%).

###### 

Baseline demographic and clinicopathological characteristics of 378 patients with solid pseudopapillary neoplasm (2004‐2017)

  Characteristics                 Numbers (n)   Percentage
  ------------------------------- ------------- ------------
  Age                                           
  ≤30                             87            23.0
  30‐64                           177           46.8
  ≥65                             114           30.2
  Sex                                           
  Male                            132           34.9
  Female                          246           65.1
  Race                                          
  White                           277           73.3
  American Indian/Alaska Native   3             0.8
  Asian or Pacific Islander       47            12.4
  Black                           47            12.4
  Unknown                         4             1.1
  Marital status at diagnosis                   
  Married                         174           46.0
  Single or Unmarried             124           32.8
  Divorced or Separated           26            6.9
  Widowed                         30            7.9
  Unknown                         24            6.3
  Surgical procedures                           
  0                               48            12.7
  1                               4             1.1
  2                               166           43.9
  3                               102           27.0
  4                               50            13.2
  5                               8             2.1
  Received radiotherapy                         
  Yes                             35            9.3
  No                              343           90.7
  Received chemotherapy                         
  Yes                             80            21.2
  No/unknown                      298           78.8
  Tumor location                                
  Head of pancreas                202           53.4
  Body of pancreas                54            14.3
  Tail of pancreas                115           30.4
  Unknown                         7             1.9
  SEER historic stage                           
  Localized                       219           57.9
  Regional                        128           33.9
  Distant                         24            6.3
  Unstaged                        7             1.9
  Tumor size (mm)                               
  Mean ± SD                       48.1 ± 33.9   
  ≤40                             181           47.9
  \>40                            191           50.5
  Unknown                         6             1.6
  Lymph nodes positive                          
  0 LN+                           320           84.7
  1‐3 LN+                         26            6.9
  ≥4 LN+                          16            4.2
  Unknown                         16            4.2
  Distant metastases                            
  M0                              349           92.3
  M1                              24            6.4
  Unknown                         5             1.3

Surgical procedures: 0: No surgery of primary site; 1: local excision of tumor; 2: partial pancreatectomy and partial or local pancreatectomy and duodenectomy without distal/partial gastrectomy; 3: Whipple\'s procedure; 4: Total pancreatectomy and subtotal gastrectomy or duodenectomy and extended pancreatoduodenectomy; and 5: other surgical approaches; LN: Lymph nodes.
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3.2. Survival analysis and prognostic factors {#cam43180-sec-0012}
---------------------------------------------

In this study, the median follow‐up time was 44 months (range, 1‐154 months). During follow‐up, 103 (27.2%) deaths occurred, of which 80 deaths were attributed to SPN (Table S1). The OS and DSS of patients with SPN are shown in Figure [2A,B](#cam43180-fig-0002){ref-type="fig"}. We found that the survival time of patients with SPN was optimistic. The 1‐, 3‐, and 5‐year overall survival rates were 98.9%, 95.7%, and 93.7%, respectively. For DSS, the 1‐, 3‐, and 5‐year survival rates were 99.2%, 96.0%, and 93.2%, respectively. Additionally, we found that only a small proportion of patients with SPN had four or more positive lymph nodes (4.2%) and distant metastasis (6.4%) (Table [1](#cam43180-tbl-0001){ref-type="table"}; Figure [2C,D](#cam43180-fig-0002){ref-type="fig"}).

![Solid pseudopapillary neoplasm (SPN) exhibited indolent behaviors. A, Survival analysis for overall survival in patients with SPNs; B, Survival analysis for disease‐specific survival in patients with SPNs; C, Lymph nodes metastasis status in SEER cohorts; D, Distant metastasis status in SEER cohorts](CAM4-9-6030-g002){#cam43180-fig-0002}

Next, we used univariate Cox regression to analyze the factors associated with OS and DSS in patients with SPN (Tables S2 and S3). The univariate analysis revealed that age, sex, surgery experience, tumor location, tumor size, lymph node metastasis, and distant metastasis were all significant prognostic factors for OS and DSS of patients with SPN. We found that patients with SPN who underwent surgical interventions had significantly better OS and DSS than those without surgical interventions (*P* \< .001; Figure [3](#cam43180-fig-0003){ref-type="fig"}). The 1‐ and 3‐year overall survival rates in the surgery group were 98.5% and 97.2%, respectively, compared with 78.8% and 33.5% in the nonsurgery group (*P* \< .001; Figure [3A](#cam43180-fig-0003){ref-type="fig"}). For DSS, the 1‐ and 3‐year survival rates for patients without surgery interventions were 76.3% and 25.4%, respectively, which were significantly lower than those for patients with surgery interventions (*P* \< .001; Figure [3A](#cam43180-fig-0003){ref-type="fig"}). Interestingly, we found that regardless of stage, patients still had better survival after surgery than those without surgery (*P* \< .001; Figure [3B,C](#cam43180-fig-0003){ref-type="fig"}). For lymphadenectomy, patients who received lymphatic dissection had significantly better OS and DSS than those without lymphatic dissection (*P* \< .001; Figure [4A‐C](#cam43180-fig-0004){ref-type="fig"}).

![Survival analysis for overall survival and disease‐specific survival in patients with solid pseudopapillary neoplasm based on surgical intervention](CAM4-9-6030-g003){#cam43180-fig-0003}

![Survival analysis for overall survival and disease‐specific survival in patients with solid pseudopapillary neoplasm based on lymphadenectomy](CAM4-9-6030-g004){#cam43180-fig-0004}

Prognostic factors of OS and DSS were further assessed by multivariate Cox regression models, which revealed that age (*P* \< .001), sex (*P* \< .05), surgery experience (*P* \< .001), lymph node metastasis status (*P* \< .001), and distant metastasis status (*P* \< .001) were all independent prognostic factors. However, marital status, tumor size, and tumor location were not found to be significant factors (Tables S2 and S3).

3.3. Sex pattern {#cam43180-sec-0013}
----------------

Based on sex, we divided the cohort into male and female groups. Their characteristics were compared and are illustrated in Table [2](#cam43180-tbl-0002){ref-type="table"}. We observed that female SPN occurred more frequently at the body/tail of the pancreas (54.7%) than male SPN (28.1%). Male patients were less frequently diagnosed at a localized stage (48.5%) than female patients (64.9%). We also found that almost half (49.2%) of male patients were diagnosed at 65 years and older, whereas most (80.1%) female patients were diagnosed younger than 65 years (Table [2](#cam43180-tbl-0002){ref-type="table"} and Figure [5A](#cam43180-fig-0005){ref-type="fig"}). As the age‐frequency distribution showed, male SPN demonstrated a unimodal skewness distribution with peak incidence at approximately age 64 years (median age). However, female SPN showed a bimodal distribution with early‐onset and late‐onset peak incidence at 28 (lower quartile age) and 62 years (upper quartile age) (Figure [5B](#cam43180-fig-0005){ref-type="fig"}).

###### 

Comparison of selected clinicopathological characteristics between male and female with solid pseudopapillary neoplasm

  Characteristics               Male   Female   *P*   \<65 years female   ≥65 years female                                      *P*                         
  ----------------------------- ------ -------- ----- ------------------- ----------------------------------------------------- ------ ------ ------ ------ -----------------------------------------------------
  Age                                                                                                                                                       
  ≤30                           6      4.5      81    32.9                **.000** [\*\*](#cam43180-note-0005){ref-type="fn"}                               
  30‐64                         61     46.2     116   47.2                                                                                                  
  ≥65                           65     49.2     49    19.9                                                                                                  
  Race                                                                                                                                                      
  White                         103    78.0     174   70.7                .304                                                  134    68.0   40     81.6   .131
  Black                         13     9.8      34    13.8                                                                      31     15.7   3      6.1    
  Others/unknown                16     12.1     38    15.4                                                                      32     16.2   6      12.2   
  Marital status at diagnosis                                                                                                                               
  Unmarried                     28     21.2     96    39.0                **.000** [\*\*](#cam43180-note-0005){ref-type="fn"}   90     45.7   6      12.2   **.000** [\*\*](#cam43180-note-0005){ref-type="fn"}
  Married                       78     59.1     96    39.0                76                                                    38.6   20     40.8          
  Others/unknown                26     19.7     54    22.0                31                                                    15.7   23     46.9          
  Received operation                                                                                                                                        
  No                            22     16.7     26    10.6                .090                                                  15     7.6    11     22.4   **.003** [\*](#cam43180-note-0004){ref-type="fn"}
  Yes                           110    88.3     220   89.4                182                                                   92.4   38     77.6          
  Tumor location                                                                                                                                            
  Head of pancreas              92     71.9     110   45.3                **.000** [\*\*](#cam43180-note-0005){ref-type="fn"}   78     39.8   32     68.1   **.000** [\*\*](#cam43180-note-0005){ref-type="fn"}
  Body/tail of pancreas         36     28.1     133   54.7                118                                                   60.2   15     31.9          
  SEER historic stage                                                                                                                                       
  Localized                     64     48.5     155   64.9                **.003** [\*](#cam43180-note-0004){ref-type="fn"}     130    68.4   25     51.0   .065
  Reginal                       56     42.4     72    30.1                51                                                    26.8   21     42.9          
  Distant                       12     9.1      12    5.0                 9                                                     4.7    3      6.1           
  Tumor size (mm)                                                                                                                                           
  ≤40                           64     49.2     117   48.3                .871                                                  82     42.3   35     72.9   **.000** [\*\*](#cam43180-note-0005){ref-type="fn"}
  \>40                          66     508      125   51.7                112                                                   57.7   13     27.1          
  Lymph nodes positive                                                                                                                                      
  0 LN+                         109    83.2     211   89.4                .089                                                  174    92.1   37     78.7   **.008** [\*](#cam43180-note-0004){ref-type="fn"}
  ≥1 LN+                        22     16.8     25    10.6                15                                                    7.9    10     21.3          
  M                                                                                                                                                         
  M0                            120    90.9     229   93.1                .122                                                  183    92.9   46     93.9   .713
  M1                            12     9.1      12    4.9                 9                                                     4.6    3      66.1          

The unknown variables were not included.

*P* \< .05.

*P* \< .001.

John Wiley & Sons, Ltd

![Solid pseudopapillary neoplasm (SPN) presented gender‐related discrepancies. A, Age‐gender distribution of male SPN and female SPN; B, Age‐frequency distribution of male SPN and female SPN; C, Survival analysis for overall survival and disease‐specific survival comparing male and female patients with SPN](CAM4-9-6030-g005){#cam43180-fig-0005}

Considering the age of natural menopause and the population characteristics in our cohort, we divided female patients into two groups: younger than 65 years and 65 years and older, representing premenopausal females and postmenopausal females, respectively. Interestingly, we observed that the tumor size in premenopausal females was significantly larger than that in postmenopausal females (Figure [6A](#cam43180-fig-0006){ref-type="fig"}).

![The difference between premenopausal female and postmenopausal female. A, Survival analysis for overall survival and disease‐specific survival comparing premenopausal female and postmenopausal female with solid pseudopapillary neoplasm (SPN); B, Tumor size distribution of SPN in premenopausal female and postmenopausal female](CAM4-9-6030-g006){#cam43180-fig-0006}

Survival analysis revealed that male patients had significantly poorer OS and DSS than female patients (*P* \< .001, Figure [5C](#cam43180-fig-0005){ref-type="fig"}). For female, OS and DSS of postmenopausal patients were significantly poorer than postmenopausal patients (*P* \< .001, Figure [6B](#cam43180-fig-0006){ref-type="fig"}).

Next, we performed univariate and multivariate analyses based on sex, and we observed that factors affecting survival differed. In male patients, univariate analysis found that factors related to overall survival included age, surgery experience, stage, the number of positive lymph nodes, and distant metastasis status (Table S4). In addition to the above factors, tumor location was found to be a prognostic factor in the female group (Table S4). For DSS, tumor size was significantly associated with prognosis for male SPN (Table S5), but it was not a significant prognostic factor for female SPN. Additionally, tumor site was not a prognostic factor in male patients but was considered a prognostic factor in female patients (Table S5). The multivariate analysis with Cox regression showed that age, surgery performance, and distant metastasis status were independent variables associated with OS and DSS in male patients (Tables [3](#cam43180-tbl-0003){ref-type="table"} and [4](#cam43180-tbl-0004){ref-type="table"}). However, distant metastasis status was not found to be an independent prognostic factor for female patients and the number of positive lymph nodes was considered a prognostic factor in female patients (Tables [3](#cam43180-tbl-0003){ref-type="table"} and [4](#cam43180-tbl-0004){ref-type="table"}).

###### 

Multivariate analysis of factors associated with overall survival for patients with solid pseudopapillary neoplasms

  Characteristics                    Male                                                  Female                                                                                       
  ---------------------------------- ----------------------------------------------------- ----------- -------------- ----------------------------------------------------- ----------- ---------------
  Age                                                                                                                                                                                   
  \<65                                                                                     Reference                                                                        Reference   
  ≥65                                **.015** [\*](#cam43180-note-0007){ref-type="fn"}     2.159       1.163‐4.009    **.000** [\*\*](#cam43180-note-0008){ref-type="fn"}   6.247       2.922‐13.352
  Marital status at diagnosis                                                                                                                                                           
  Single or unmarried                                                                      Reference                                                                        Reference   
  Married                            .504                                                  1.339       0.559‐3.151    .784                                                  1.132       0.467‐2.476
  Divorced or separated or widowed   **.009** [\*](#cam43180-note-0007){ref-type="fn"}     3.990       1.413‐1.267    0.873                                                 1.085       0.101‐2.939
  Received surgery                                                                                                                                                                      
  No                                                                                       Reference                                                                        Reference   
  Yes                                **.000** [\*\*](#cam43180-note-0008){ref-type="fn"}   0.224       0.107‐0.472    **.002** [\*](#cam43180-note-0007){ref-type="fn"}     0.243       0.098‐0.603
  Tumor location                     NI                                                                                                                                                 
  Head of pancreas                                                                                                                                                          Reference   
  Body/tail of pancreas                                                                                               .266                                                  0.617       0.264‐1.443
  Tumor size (mm)                                                                                                     NI                                                                
  ≤40                                                                                      Reference                                                                                    
  \>40                               .921                                                  1.021       0.561‐1.897                                                                      
  Lymph nodes positive                                                                                                                                                                  
  0 LN+                                                                                    Reference                                                                        Reference   
  1‐3 LN+                            .219                                                  0.434       0.114‐1.643    **.000** [\*\*](#cam43180-note-0008){ref-type="fn"}   6.034       2.367‐15.377‐
  ≥4 LN+                             **.002** [\*](#cam43180-note-0007){ref-type="fn"}     4.104       1.660‐10.148   **.000** [\*\*](#cam43180-note-0008){ref-type="fn"}   13.404      4.401‐40.823
  M                                                                                                                                                                                     
  M0                                                                                       Reference                                                                        Reference   
  M1                                 **.000** [\*\*](#cam43180-note-0008){ref-type="fn"}   4.860       2.105‐11.224   .058                                                  3.419       0.960‐12.177

Abbreviation: NI, not included in multivariate survival analysis.

*P* \< .05.

*P* \< .001.

John Wiley & Sons, Ltd

###### 

Multivariate analysis of factors associated with disease‐specific survival for patients with solid pseudopapillary neoplasms

  Characteristics                    Male                                                  Female                                                                                       
  ---------------------------------- ----------------------------------------------------- ----------- -------------- ----------------------------------------------------- ----------- --------------
  Age                                                                                                                                                                                   
  \<65                                                                                     Reference                                                                        Reference   
  ≥65                                **.021** [\*](#cam43180-note-0010){ref-type="fn"}     2.260       1.129‐4.523    **.000** [\*\*](#cam43180-note-0011){ref-type="fn"}   8.698       3.454‐21.907
  Marital status at diagnosis                                                                                                                                                           
  Single or unmarried                                                                      Reference                                                                        Reference   
  Married                            .246                                                  1.804       0.666‐4.886    .903                                                  0.940       0.347‐2.545
  Divorced or separated or widowed   **.003** [\*](#cam43180-note-0010){ref-type="fn"}     6.151       1.890‐20.014   .623                                                  0.740       0.223‐2.454
  Received surgery                                                                                                                                                                      
  No                                                                                       Reference                                                                        Reference   
  Yes                                **.000** [\*\*](#cam43180-note-0011){ref-type="fn"}   0.200       0.085‐0.466    **.001** [\*](#cam43180-note-0010){ref-type="fn"}     0.162       0.054‐0.487
  Tumor location                     NI                                                                                                                                                 
  Head of pancreas                                                                                                                                                          Reference   
  Body/tail of pancreas                                                                                               .140                                                  0.462       0.165‐1.290
  Tumor size (mm)                                                                                                     NI                                                                
  ≤40                                                                                      Reference                                                                                    
  \>40                               .984                                                  0.993       0.487‐2.024                                                                      
  Lymph nodes positive                                                                                                                                                                  
  0 LN+                                                                                    Reference                                                                        Reference   
  1‐3 LN+                            .171                                                  0.361       0.084‐1.555    **.000** [\*\*](#cam43180-note-0011){ref-type="fn"}   7.318       2.538‐21.097
  ≥4 LN+                             **.021** [\*](#cam43180-note-0010){ref-type="fn"}     3.515       1.209‐10.218   **.000** [\*\*](#cam43180-note-0011){ref-type="fn"}   16.937      5.111‐56.132
  M                                                                                                                                                                                     
  M0                                                                                       Reference                                                                        Reference   
  M1                                 **.000** [\*\*](#cam43180-note-0011){ref-type="fn"}   6.573       2.417‐17.877   .057                                                  4.436       0.954‐20.620

Abbreviation: NI, not included in multivariate survival analysis.

*P* \< .05.

*P* \< .001.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam43180-sec-0014}
=============

In our study, we analyzed the SEER database of 378 patients with SPN and mainly elaborated the following three points:

First, we evaluated the biological behavior of SPNs by analyzing demographic and clinicopathological characteristics. Consistent with conventional views, we observed that SPN exhibited indolent behaviors with a relatively low risk of lymph node metastasis (12.4%) and distant metastasis (4.5%) in the SEER cohort. Most patients with SPN were diagnosed at the localized stage (85.1%). We also found that the SPN showed a favorable prognosis. The 1‐, 3‐, and 5‐year DSS rates were 98.9%, 95.7%, and 93.7%.

Second, we assessed the effect of surgery treatments on patients with SPN. Previous evidence confirmed that surgical resection was an effective approach to treat SPN, and satisfactory outcomes could be obtained by tumor debulking.[^13^](#cam43180-bib-0013){ref-type="ref"}, [^14^](#cam43180-bib-0014){ref-type="ref"}, [^15^](#cam43180-bib-0015){ref-type="ref"} In our study, we demonstrated similar results in that patients with SPN after surgical resection had significantly better OS and DSS than those without surgical resection. Meanwhile, we identified that patients diagnosed at distant stages still had more favorable survival after surgical debulking than those without surgical debulking. However, the validity of lymphadenectomy remains a controversial issue. Some researchers claimed that there was no need to undertake formal lymphadenectomy routinely,[^16^](#cam43180-bib-0016){ref-type="ref"}, [^17^](#cam43180-bib-0017){ref-type="ref"} whiles other reported that lymphatic dissection is necessary.[^14^](#cam43180-bib-0014){ref-type="ref"}, [^18^](#cam43180-bib-0018){ref-type="ref"} We found that patients with lymphatic dissection had a significantly better prognosis than those without lymphatic dissection. Thus, surgical resection guarantees the good prognosis, but further studies need to evaluate the effectiveness of lymphatic dissection. Moreover, in view of long‐term survival and low‐grade malignancy, organ‐preserving surgery, such as duodenum‐preserving pancreatic head resection and spleen‐preserving resection, and laparoscopic surgery will be encouraged in specialized pancreatic centers.[^19^](#cam43180-bib-0019){ref-type="ref"}, [^20^](#cam43180-bib-0020){ref-type="ref"}, [^21^](#cam43180-bib-0021){ref-type="ref"}

Last but not least, investigating the sex feature of SPNs. In our current study, SPN showed a predilection for females in 65.1% of all cases. It is worth noting the distinctly different patterns of onset between males and females. We revealed that female SPNs showed a bimodal age‐frequency distribution, while male SPNs demonstrated a unimodal skewness distribution. Moreover, we found that female SPN had an early‐onset incidence at 28 years and a late‐onset peak incidence at 62 years, while male SPN had a peak incidence at approximately 64 years of age. Previous evidence implied that sex hormones might participate in the pathogenesis of SPN.[^20^](#cam43180-bib-0020){ref-type="ref"}, [^22^](#cam43180-bib-0022){ref-type="ref"} Strong immunoreactivity for progesterone has been identified in many studies.[^11^](#cam43180-bib-0011){ref-type="ref"}, [^12^](#cam43180-bib-0012){ref-type="ref"}, [^23^](#cam43180-bib-0023){ref-type="ref"} Case reports showed that SPN grew rapidly during pregnancy,[^24^](#cam43180-bib-0024){ref-type="ref"}, [^25^](#cam43180-bib-0025){ref-type="ref"}, [^26^](#cam43180-bib-0026){ref-type="ref"} and progesterone might act as an oncogenic factor in SPN. For estrogen, Tognarini I et al demonstrated the strong expression of ER in tumor tissue and the proliferative action of estrogen in vitro, offering potential treatment strategies for SPN via selective ER modulators.[^27^](#cam43180-bib-0027){ref-type="ref"} Similarly, another study reported that antiestrogen drugs for cases with unresectable liver metastasis resulted in a favorable prognosis.[^28^](#cam43180-bib-0028){ref-type="ref"} Therefore, in our study, we presumed that the early onset in women might be attributed to exposure to progesterone and/or estrogen during the reproductive period, while the late onset might be attributed to accumulated lifetime environmental exposure.

The age of natural menopause varies by individual, race, and ethnicity, with a range of 40‐60.[^29^](#cam43180-bib-0029){ref-type="ref"}, [^30^](#cam43180-bib-0030){ref-type="ref"} Considering the age of natural menopause and population characteristics in our cohort, we divided female patients into two groups: younger than 65 years and 65 years and older, representing premenopausal females and postmenopausal females, respectively. Interestingly, we observed that the tumor size in premenopausal females was significantly larger than that in postmenopausal females. It indicated that female hormones affect the growth of SPNs and that anti‐female hormone agents may be a promising adjuvant. However, the function of female hormones in development has not yet reached consensus and needs further study.

Our study also revealed that male patients had significantly poorer OS and DSS than female patients. This difference may be because male SPNs had a higher percentage of patients older than 65 years than female SPNs. Reported surveys and our analysis consistently identified that older age was an independent prognostic risk factor for SPN.[^10^](#cam43180-bib-0010){ref-type="ref"}, [^31^](#cam43180-bib-0031){ref-type="ref"} In addition, we found that the clinicopathological characteristic profiles were more similar for male SPN and postmenopausal female SPN. To our knowledge, our study is the first to describe this phenomenon in a male population. Moreover, it could partly explain that despite the larger tumor size in premenopausal females, the OS and DSS of premenopausal females were significantly better than those of postmenopausal females.

There are several limitations in our current population‐based study. First, due to the indolent behavior of SPNs, it was difficult to conduct large prospective studies. Our study is retrospective and may inevitably include biases, which affect the analysis. Second, the rarity of SPN in nature and the lower number of patients in the subgroups based on sex and age results in limited statistical power. Third, the lack of detailed information about chemotherapy and radiation made it difficult to evaluate their effect on SPN. Meanwhile, information on recurrence was not recorded, and factors that contributed to the sex disparities, such as serum levels of estrogen, progestogen, androgen, menstrual status, and reproductive histories, were not available in the SEER database. Therefore, it is difficult to precisely assess the difference between female and male patients with SPN at different ages. To better understand these complicated sex disparities and the role of sex hormones in the development of SPN, further clinical and fundamental research is needed. Despite these limitations, this is the first study that is large enough to demonstrate that male SPN was different from female SPN, which suggests that different treatment strategies should be designed for patients of different sexes at different ages and implies the possibility of hormone therapy.

5. CONCLUSION {#cam43180-sec-0015}
=============

In conclusion, this population‐based study demonstrated that SPN present indolent behavior and predominantly occurs in young women. Regardless of stage, surgical intervention is recommended. Moreover, our study is the first large enough study to emphasize the sex‐related discrepancies in SPN, and to observe that clinicopathological characteristic profiles were more common for male SPN and postmenopausal female SPN. Thus, different treatment strategies should be designed for patients with different genders at different ages and hormone therapy was a promising approach.
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